NEW YORK (GenomeWeb News) – Vermillion said today that it has tapped investment bank ThinkPanmure to help it identify and evaluate “strategic alternatives” for maximizing shareholder value.
Vermillion said it plans to work with ThinkPanmure on ways to “enhance the potential” of its OVA1 and VASCLIR proteomic tests and its pipeline of proprietary biomarkers, but added that “no assurances can be given that this evaluation will lead to any specific action or transaction.”
The company did not disclose further details on the strategic alternatives it is considering.
Vermillion in late June filed for clearance from the US Food and Drug Administration for its OVA1 ovarian tumor triage test.
In May, it began a clinical study to support clearance of its VASCLIR test for peripheral arterial disease.